Want to see AU:HMD full AI Analyst Report?
HMD Stock Chart & Stats
AU$0.04
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.04
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume370.09K
Average Volume (3M)1.96M
Market Cap
AU$44.03M
Enterprise ValueAU$19.93M
Total Cash (Recent Filing)AU$914.65K
Total Debt (Recent Filing)AU$282.39K
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetDeleveraging to zero debt and a small positive equity balance materially lowers solvency and interest-risk across 2–6 months. A debt-free position improves financing flexibility and reduces fixed financing costs, providing a firmer platform for product investment or fundraising.
Improved Gross MarginsA sustained jump to ~60% gross margin indicates stronger unit economics from devices/software mix or cost improvements. Durable gross margin expansion creates room to absorb operating expenses as revenue scales, supporting a clearer path to operating leverage if top-line stabilizes.
Focused Maternal-fetal Digital HealthSpecialization in maternal and fetal remote-monitoring taps a structural telehealth trend and clinical continuity need. Focused product set and clinical decision support can build durable differentiation, stickier clinical relationships, and recurring software/service revenue over time.
Bears Say
Persistent Cash BurnChronic negative operating and free cash flow forces continual funding needs and raises liquidity risk. Over months this constrains R&D, commercialization, and hiring, and requires external capital or deep margin improvement to avoid dilution or operational cutbacks.
Consistent Operating LossesSustained net losses erode equity and limit internal reinvestment capacity. Negative margins across periods indicate the company has not converted gross-margin gains into operating profitability, making achievement of durable positive returns uncertain without structural cost or revenue change.
Revenue Volatility And Recent ContractionA shrinking and inconsistent top line undermines operating leverage from improved gross margins. Revenue contraction impedes predictable scaling, complicates forecasting and market expansion, and lengthens the timeline to profitability absent sustained demand recovery.
HeraMED Ltd. News
HMD FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$44.03M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 30 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,158,636,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-68.43%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Uscom Limited
―
Atomo Diagnostics Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―